Skip to main content

Table 4 Multivariate logistic regression showing risk factors for preterm birth in HAART-exposed women irrespective of infant HIV status

From: Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study

Variable

Preterm Birth (<37 weeks)

 

Early HAART

Late HAART

 

Univariate analysis

Multivariate analysis (n = 455)

Univariate analysis

Multivariate analysis (n = 477)

 

OR (95% CI)

AOR (95% CI)

P

OR (95% CI)

AOR (95% CI)

P

HAART-unexposed

1.00

1.00

 

1.00

1.00

 

HAART-exposed

      

PI-based

3.39 (1.38-8.36)

3.00 (1.07-8.38)

0.036

0.64 (0.23-1.76)

0.70 (0.23-2.13)

0.53

NVP-based

6.30 (2.72-13.56)

5.41 (2.14-13.70)

<0.001

2.10 (0.79-5.59)

1.88 (0.61-5.80)

0.27

EFV-based

6.40 (2.60-15.65)

5.64 (2.09-15.16)

0.001

1.00 (0.12-8.56)

1.47 (0.15-14.10)

0.74

CD4 cell count

      

per category increase*

0.69 (0.58-0.83)

0.68 (0.55-0.85)

0.001

0.78 (0.57-1.07)

0.80 (0.55-1.15)

0.22

Maternal age

      

16-24 years

1.00

1.00

 

1.00

1.00

 

25-29 years

0.90 (0.42-1.89)

0.91 (0.37-2.21)

0.83

5.35 (1.2-23.75)

9.17 (1.17-72.0)

0.035

30-34 years

1.12 (0.54-2.33)

1.08 (0.45-2.57)

0.86

2.22 (0.46-10.66)

3.46 (0.41-29.45)

0.26

≥35 years

2.12 (0.98-4.57)

2.09 (0.83-5.25)

0.12

1.13 (0.16-8.18)

1.91 (0.17-21.66)

0.60

Hypertension

      

no

1.00

1.00

 

1.00

1.00

 

yes

1.83 (0.88-3.80)

1.95 (0.87-4.36)

0.11

0.96 (0.22-4.26)

0.84 (0.18-3.90)

0.83

  1. HAART - highly active antiretroviral treatment; early HAART - HAART initiation <28 weeks of pregnancy; late HAART - HAART initiation at ≥28 weeks of pregnancy; PI - protease inhibitor, NVP - nevirapine; EFV - efavirenz;; OR - odds ratio; AOR - adjusted odds ratio; CI (95%) - 95% confidence interval
  2. *CD4 categories: (cells/mm3): 0-49 (baseline category), 50-99, 100-149, 150-199 and 200-250